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Ivermectin for COVID-19:  
Promising but not yet conclusive
To the Editor: Ivermectin has been proposed as a potential defini­
tive and prophylactic treatment for COVID­19.[1] Ivermectin is an 
anthelmintic drug that is usually indicated for filarial and resistant 
scabies infections, but has been shown to have antiviral activity and 
anti­inflammatory activity in vitro.[2,3] Ivermectin has the potential to 
be a promising directed therapy in the drug armamentarium against 
COVID­19, as it has been shown to have in vitro activity against 
SARS­CoV­2.[4]
Several randomised controlled trials (RCTs) and observational 
studies have reported on the effectiveness and safety outcomes of 
ivermectin in COVID­19.[1,5] These data are very promising, showing 
large treatment effects and acceptable adverse effect profiles for 
ivermectin against COVID­19, especially when combined in meta­
analyses.
While they are certainly promising, caution should be exercised 
when interpreting these meta­analyses, as the pooling of 
heterogeneous trials with different methodologies, outcomes and 
comparators may make the conclusions drawn unreliable. Much 
of the currently available published and peer­reviewed evidence is 
from either observational or uncontrolled studies.[1,5] Observational 
data do not have the same strength of evidence or the methodology 
to account for biases and confounders that RCTs have.[6] As a recent 
example, the widely proclaimed benefits of hydroxychloroquine and 
chloroquine from observational studies proved to be unfounded in 
larger RCTs.[7,8] The National Department of Health in South Africa 
(SA) also released its own evidence summary on 21 December 2020, 
using a rapid review process to formulate a recommendation. [5] The 
evidence summary concluded that, based on the current RCT data 
available, ivermectin should not be used for adults with COVID‐19, 
but that eligible patients should be considered for enrolment in 
relevant therapeutic trials.[5] Nonetheless, although the rapidly 
evolving data may currently be interpreted as inconclusive based on 
methodological factors and small sample sizes of individual studies, 
the combined trend of results indicates that ivermectin holds promise 
as a directed therapy against COVID­19.
The optimal dose of ivermectin against SARS­CoV­2 has not yet 
been determined. It is possible that the blood concentrations of 
ivermectin required to achieve antiviral activity are much higher 
than what would be attained with doses being given for parasitic 
infections. The article by Caly et al.[4] on the in vitro activity of 
ivermectin against SARS­CoV­2 determined the required ivermectin 
concentrations to be in the microgram range, whereas the blood 
concentrations usually achieved with standard­dose ivermectin are 
in the nanogram range.[2,9,10] Higher than standard ivermectin doses 
appear to be safe in humans,[11] but at the time of writing there is 
still much uncertainty regarding the human dose required to achieve 
antiviral activity and a favourable benefit­to­risk balance.
Ivermectin is not registered for human use in SA, but may 
be obtained through named patient­basis approval (Section 21 
approval). The South African Health Products Regulatory Authority 
(SAHPRA) recently issued an announcement in response to 
public media releases, unequivocally stating that ivermectin is not 
indicated or approved by SAHPRA for use in humans, but that 
it encourages and supports all well­designed, ethically approved 
scientific studies. [12] Advocacy groups should continue to lobby for 
timeous and appropriate access to COVID­19 interventions that have 
supporting evidence of efficacy and safety. Data for ivermectin from 
larger RCTs are expected in early 2021. However, while awaiting data 
from clinical trials in SA or abroad, the public as well as healthcare 
professionals should support the governing processes already in place 
for the rapid and effective review of the available evidence of COVID­
19 interventions.
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